Relay Therapeutics, Inc. Common Stock

RLAYNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
19.46 USD
↘ 1.11 (5.40%)AT CLOSE (11:59 AM EDT)
19.66
↗ 0.20 (1.00%)
POST MARKET (AS OF 07:39 PM EDT)
Post Market
AS OF 07:39 PM EDT
19.66
↗ 0.20 (1.00%)
🔴Market: CLOSED

Relay Therapeutics, Inc. Common Stock (RLAY) trades at $19.45 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, RLAY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Aug 26, 2026.

Open?$19.95
High?$20.12
Low?$19.19
Prev. Close?$20.57
Volume?2.9M
Avg. Volume?2.3M
VWAP?$19.52
Rel. Volume?1.30x
Bid / Ask
Bid?$19.02 × 200
Ask?$19.97 × 100
Spread?$0.95
Midpoint?$19.49
Valuation & Ratios
Market Cap?4.3B
Shares Out?219.1M
Float?169.5M
Float %?77.3%
P/E Ratio?N/A
P/B Ratio?4.79
EPS?-$1.31
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
192
Market Cap
4.5B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.relaytx.com
Listed
2020-07-16
Address
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02139
Phone: 617-370-8837
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
17
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?31.82Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.40%Squeeze Risk
Short Interest?41.4M
Days to Cover?21.6
Free Float169.5M
Avg Daily Volume1.9M
Settlement Date2026-08-14
Financial Health
Current Ratio?18.27Strong
Quick Ratio?18.27Strong
Cash Ratio?2.39Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
38
4.79FAIR▾
P/S?
Peers
100
S&P
3
412.03HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-13.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
400.32HIGH▾
Returns & Efficiency
ROE?
S&P
6
-32.2%WEAK▾
ROA?
S&P
3
-29.6%WEAK▾
Cash Flow & Enterprise
FCF?$-212205000
Enterprise Value?$4.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist